MedPath

Neuracle Science Co., Ltd.

🇰🇷South Korea
Ownership
Holding
Established
2015-10-01
Employees
251
Market Cap
-
Website
http://www.neuracles.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients

Phase 1
Recruiting
Conditions
Seneorineural Deafness
Sudden Sensorineural Hearing Loss
Interventions
Biological: Placebo
First Posted Date
2024-02-08
Last Posted Date
2024-10-11
Lead Sponsor
Neuracle Science Co., LTD.
Target Recruit Count
118
Registration Number
NCT06249919
Locations
🇰🇷

SCH University Hospital Bucheon, Bucheon, Korea, Republic of

🇰🇷

Chonam National University Hospital, Gwangju, Korea, Republic of

🇰🇷

Inje University Ilsan Paik Hospital, Ilsan, Korea, Republic of

and more 12 locations

A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion

Phase 1
Completed
Conditions
Neurodegenerative Diseases
Interventions
Drug: NS101 IV infusion
First Posted Date
2021-12-03
Last Posted Date
2022-12-23
Lead Sponsor
Neuracle Science Co., LTD.
Target Recruit Count
64
Registration Number
NCT05143463
Locations
🇨🇦

Syneos Health, Québec, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.